Abstract Body

Pre-exposure prophylaxis (PrEP) persistence and adherence are critical to achieving national HIV prevention goals. While there is no gold standard for measuring PrEP persistence (continued use) and adherence (effective use), biological testing for tenofovir diphosphate (TFV-DP) and emtricitabine (FTC) is considered best practice. We conducted testing for PrEP among HIV-negative men who have sex with men (MSM) in 4 U.S. cities as part of 2017 National HIV Behavioral Surveillance.

MSM were recruited via venue-based sampling in Los Angeles, Philadelphia, San Francisco, and Washington DC. Eligible, consenting MSM completed a survey, HIV testing, and dried blood spot (DBS) collection. DBS were tested for tenofovir (TFV), FTC, and TFV-DP by liquid chromatography mass spectrometry. Our analysis was limited to HIV-negative MSM who had CDC-based PrEP indications and self-reported PrEP use in the past year. Persistence was defined as self-reporting PrEP use in the past 12 months and having any detectable TFV, FTC, or TFV-DP in DBS collected at the interview. Among those reporting past-month PrEP use, adherence was defined as TFV-DP ≥1250 fmol/punch or TFV-DP ≥700 fmol/punch (consistent with an average of 7 doses/week or 4-7 doses/week, respectively). Poisson regression with generalized estimating equations clustering by recruitment event and adjusting for city was used to assess associations between key characteristics and persistence and adherence.

Overall, 81.2% (310/382) were persistently using PrEP based on biological testing. Persistence was significantly lower among MSM who were younger (p=0.03), had lower education (p<0.01), had public insurance (p=0.02), and had fewer male sex partners (p<0.01). Among MSM reporting past-month PrEP use, 66.2% (200/302) were adherent at 7 doses/week and 80.5% (243/302) were adherent at 4-7 doses/week. Adherence was significantly lower among MSM who were younger (all p<0.01), had less than high school education (p=0.02, p=0.04), were black race/ethnicity (p=0.04, p=0.01), had fewer male sex partners (p=0.03, p=0.05), and lived in Philadelphia (p<0.01, p=0.01).

Approximately 19% of PrEP-using MSM in the 4 cities had not persistently used PrEP. About 34% of MSM were not adherent at 7 doses/week and 20% were not adherent at 4-7 doses/week. Efforts to support PrEP persistence and adherence are needed for MSM and should include strategies tailored to age, education, race/ethnicity, insurance type, and city context.